Cargando…

Aspects of prophylactic treatment of hemophilia

Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal o...

Descripción completa

Detalles Bibliográficos
Autor principal: Ljung, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056524/
https://www.ncbi.nlm.nih.gov/pubmed/27766056
http://dx.doi.org/10.1186/s12959-016-0103-3
_version_ 1782458918331482112
author Ljung, Rolf
author_facet Ljung, Rolf
author_sort Ljung, Rolf
collection PubMed
description Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.
format Online
Article
Text
id pubmed-5056524
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50565242016-10-20 Aspects of prophylactic treatment of hemophilia Ljung, Rolf Thromb J Review Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors. BioMed Central 2016-10-04 /pmc/articles/PMC5056524/ /pubmed/27766056 http://dx.doi.org/10.1186/s12959-016-0103-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Ljung, Rolf
Aspects of prophylactic treatment of hemophilia
title Aspects of prophylactic treatment of hemophilia
title_full Aspects of prophylactic treatment of hemophilia
title_fullStr Aspects of prophylactic treatment of hemophilia
title_full_unstemmed Aspects of prophylactic treatment of hemophilia
title_short Aspects of prophylactic treatment of hemophilia
title_sort aspects of prophylactic treatment of hemophilia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056524/
https://www.ncbi.nlm.nih.gov/pubmed/27766056
http://dx.doi.org/10.1186/s12959-016-0103-3
work_keys_str_mv AT ljungrolf aspectsofprophylactictreatmentofhemophilia